| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aortic Valve Stenosis | 16 | 2025 | 189 | 5.770 |
Why?
|
| Transcatheter Aortic Valve Replacement | 15 | 2025 | 110 | 5.030 |
Why?
|
| Heart Valve Prosthesis | 12 | 2024 | 113 | 4.550 |
Why?
|
| Aortic Valve | 13 | 2024 | 190 | 2.560 |
Why?
|
| Coronary Vessels | 6 | 2021 | 119 | 2.550 |
Why?
|
| Bioprosthesis | 4 | 2021 | 42 | 2.210 |
Why?
|
| Percutaneous Coronary Intervention | 7 | 2024 | 209 | 1.860 |
Why?
|
| Vascular Calcification | 3 | 2019 | 26 | 1.770 |
Why?
|
| Heart Valve Prosthesis Implantation | 6 | 2019 | 176 | 1.710 |
Why?
|
| Coronary Angiography | 7 | 2021 | 203 | 1.640 |
Why?
|
| Coronary Stenosis | 4 | 2017 | 39 | 1.510 |
Why?
|
| Prosthesis Design | 7 | 2024 | 229 | 1.510 |
Why?
|
| Tricuspid Valve | 3 | 2017 | 25 | 1.500 |
Why?
|
| Heart Arrest | 4 | 2023 | 171 | 1.430 |
Why?
|
| Coronary Artery Disease | 5 | 2019 | 313 | 1.350 |
Why?
|
| Coronary Occlusion | 2 | 2021 | 6 | 1.260 |
Why?
|
| Balloon Valvuloplasty | 3 | 2024 | 14 | 1.200 |
Why?
|
| Atherectomy, Coronary | 2 | 2019 | 12 | 1.180 |
Why?
|
| Thromboxane B2 | 4 | 2022 | 17 | 1.130 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2021 | 226 | 1.100 |
Why?
|
| Coronary Artery Bypass | 3 | 2021 | 298 | 1.050 |
Why?
|
| Aged, 80 and over | 19 | 2024 | 5462 | 1.000 |
Why?
|
| Tricuspid Valve Stenosis | 2 | 2017 | 3 | 1.000 |
Why?
|
| Fractional Flow Reserve, Myocardial | 3 | 2016 | 19 | 0.990 |
Why?
|
| Renal Artery | 1 | 2025 | 37 | 0.930 |
Why?
|
| Heart Transplantation | 2 | 2017 | 170 | 0.880 |
Why?
|
| Treatment Outcome | 18 | 2024 | 5680 | 0.880 |
Why?
|
| Prosthesis Failure | 3 | 2024 | 77 | 0.860 |
Why?
|
| Aged | 28 | 2025 | 14447 | 0.850 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2023 | 91 | 0.850 |
Why?
|
| Acute Coronary Syndrome | 3 | 2021 | 253 | 0.810 |
Why?
|
| Humans | 54 | 2025 | 63445 | 0.810 |
Why?
|
| Defibrillators, Implantable | 3 | 2025 | 266 | 0.800 |
Why?
|
| Myocardial Infarction | 5 | 2022 | 916 | 0.800 |
Why?
|
| Stents | 4 | 2021 | 502 | 0.790 |
Why?
|
| Risk Factors | 18 | 2025 | 5354 | 0.790 |
Why?
|
| Kidney | 1 | 2025 | 446 | 0.780 |
Why?
|
| Hemodynamics | 4 | 2024 | 250 | 0.760 |
Why?
|
| Cardiac Catheterization | 3 | 2020 | 283 | 0.730 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2021 | 32 | 0.710 |
Why?
|
| Myocardial Revascularization | 2 | 2020 | 76 | 0.700 |
Why?
|
| Male | 30 | 2025 | 29891 | 0.680 |
Why?
|
| Aspirin | 2 | 2022 | 171 | 0.680 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2021 | 56 | 0.680 |
Why?
|
| Tomography, Optical Coherence | 2 | 2019 | 223 | 0.650 |
Why?
|
| Drug-Eluting Stents | 1 | 2021 | 62 | 0.650 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2021 | 168 | 0.640 |
Why?
|
| Female | 31 | 2025 | 32880 | 0.630 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2019 | 22 | 0.630 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 2 | 2021 | 14 | 0.590 |
Why?
|
| Pacemaker, Artificial | 2 | 2025 | 49 | 0.580 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2016 | 62 | 0.570 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 266 | 0.570 |
Why?
|
| Cardiac Catheters | 1 | 2018 | 11 | 0.570 |
Why?
|
| Thromboxane A2 | 1 | 2017 | 5 | 0.560 |
Why?
|
| Equipment Safety | 1 | 2017 | 22 | 0.560 |
Why?
|
| Middle Aged | 18 | 2025 | 17613 | 0.540 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2021 | 153 | 0.530 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2017 | 20 | 0.530 |
Why?
|
| Echocardiography | 5 | 2023 | 501 | 0.530 |
Why?
|
| Saphenous Vein | 2 | 2016 | 52 | 0.500 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 39 | 0.490 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 60 | 0.490 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2015 | 36 | 0.450 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 1644 | 0.440 |
Why?
|
| Ventricular Function, Left | 3 | 2022 | 268 | 0.430 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2013 | 5 | 0.420 |
Why?
|
| Hematocrit | 1 | 2013 | 34 | 0.420 |
Why?
|
| Ticlopidine | 1 | 2013 | 49 | 0.410 |
Why?
|
| Electrocardiography | 4 | 2020 | 554 | 0.400 |
Why?
|
| Heart Failure | 3 | 2022 | 913 | 0.400 |
Why?
|
| United States | 12 | 2025 | 7843 | 0.400 |
Why?
|
| Arterial Pressure | 1 | 2012 | 26 | 0.390 |
Why?
|
| Blood Platelets | 1 | 2013 | 102 | 0.390 |
Why?
|
| Coronary Circulation | 1 | 2012 | 52 | 0.390 |
Why?
|
| Thromboembolism | 1 | 2013 | 73 | 0.380 |
Why?
|
| Computed Tomography Angiography | 2 | 2025 | 126 | 0.380 |
Why?
|
| Time Factors | 9 | 2024 | 3768 | 0.370 |
Why?
|
| Heparin | 1 | 2013 | 116 | 0.370 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2012 | 19 | 0.370 |
Why?
|
| Registries | 5 | 2024 | 888 | 0.360 |
Why?
|
| Heart Rate | 1 | 2013 | 322 | 0.350 |
Why?
|
| Recovery of Function | 3 | 2024 | 288 | 0.350 |
Why?
|
| Heart Valve Diseases | 3 | 2018 | 95 | 0.340 |
Why?
|
| Patient Readmission | 3 | 2025 | 429 | 0.330 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2023 | 44 | 0.330 |
Why?
|
| Acute Kidney Injury | 2 | 2022 | 141 | 0.320 |
Why?
|
| Heart Diseases | 1 | 2012 | 218 | 0.310 |
Why?
|
| Multidetector Computed Tomography | 2 | 2020 | 21 | 0.300 |
Why?
|
| Stroke Volume | 3 | 2022 | 329 | 0.300 |
Why?
|
| Anticoagulants | 1 | 2013 | 495 | 0.300 |
Why?
|
| Hospitals | 2 | 2021 | 393 | 0.290 |
Why?
|
| Echocardiography, Doppler | 2 | 2019 | 133 | 0.280 |
Why?
|
| Equipment Design | 2 | 2017 | 352 | 0.250 |
Why?
|
| Reoperation | 2 | 2018 | 293 | 0.250 |
Why?
|
| Retrospective Studies | 11 | 2025 | 6658 | 0.250 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 937 | 0.240 |
Why?
|
| Disease Management | 2 | 2017 | 232 | 0.240 |
Why?
|
| Incidental Findings | 1 | 2025 | 44 | 0.230 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 2458 | 0.230 |
Why?
|
| Sarcoidosis | 1 | 2025 | 33 | 0.230 |
Why?
|
| Risk Assessment | 4 | 2024 | 2079 | 0.220 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 1553 | 0.220 |
Why?
|
| Ventricular Fibrillation | 1 | 2025 | 106 | 0.220 |
Why?
|
| Foreign-Body Migration | 1 | 2024 | 23 | 0.220 |
Why?
|
| Heart Ventricles | 3 | 2023 | 261 | 0.210 |
Why?
|
| Cardiomyopathies | 1 | 2025 | 125 | 0.210 |
Why?
|
| Biomarkers | 3 | 2020 | 1408 | 0.200 |
Why?
|
| Tachycardia, Ventricular | 1 | 2025 | 129 | 0.200 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 1101 | 0.200 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2024 | 90 | 0.190 |
Why?
|
| Mitral Valve Prolapse | 1 | 2021 | 11 | 0.180 |
Why?
|
| Obstetric Labor Complications | 1 | 2021 | 23 | 0.180 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2021 | 12 | 0.180 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2021 | 36 | 0.180 |
Why?
|
| Fluoroscopy | 1 | 2021 | 65 | 0.180 |
Why?
|
| Shock, Cardiogenic | 2 | 2019 | 102 | 0.170 |
Why?
|
| Dissection | 1 | 2021 | 48 | 0.170 |
Why?
|
| Postoperative Complications | 4 | 2024 | 1308 | 0.170 |
Why?
|
| Vascular Diseases | 1 | 2021 | 81 | 0.160 |
Why?
|
| Cause of Death | 2 | 2018 | 221 | 0.160 |
Why?
|
| Adult | 6 | 2025 | 16824 | 0.160 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 730 | 0.160 |
Why?
|
| Hemorrhage | 1 | 2021 | 267 | 0.160 |
Why?
|
| Atrial Pressure | 1 | 2019 | 5 | 0.150 |
Why?
|
| Ventricular Pressure | 1 | 2019 | 30 | 0.150 |
Why?
|
| Heart Valves | 1 | 2018 | 26 | 0.150 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2017 | 111 | 0.150 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2018 | 19 | 0.150 |
Why?
|
| Ventricular Remodeling | 1 | 2018 | 83 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 165 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2023 | 2570 | 0.140 |
Why?
|
| Electromagnetic Phenomena | 1 | 2017 | 5 | 0.140 |
Why?
|
| Electrocoagulation | 1 | 2017 | 13 | 0.140 |
Why?
|
| Defibrillators | 1 | 2017 | 16 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2021 | 512 | 0.140 |
Why?
|
| Urinalysis | 1 | 2017 | 38 | 0.140 |
Why?
|
| Anesthesia, Conduction | 1 | 2017 | 11 | 0.140 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2018 | 88 | 0.140 |
Why?
|
| Equipment Failure | 1 | 2017 | 67 | 0.140 |
Why?
|
| Subclavian Artery | 1 | 2017 | 26 | 0.140 |
Why?
|
| Thoracic Surgery | 1 | 2018 | 77 | 0.140 |
Why?
|
| Mitral Valve | 1 | 2018 | 121 | 0.140 |
Why?
|
| Length of Stay | 1 | 2021 | 812 | 0.140 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 89 | 0.130 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2017 | 13 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2019 | 568 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 1094 | 0.130 |
Why?
|
| Aorta, Thoracic | 1 | 2017 | 84 | 0.130 |
Why?
|
| Electric Countershock | 1 | 2017 | 101 | 0.130 |
Why?
|
| Patient Selection | 1 | 2019 | 490 | 0.130 |
Why?
|
| Hospital Mortality | 1 | 2021 | 877 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 422 | 0.130 |
Why?
|
| American Heart Association | 1 | 2017 | 126 | 0.130 |
Why?
|
| Dinoprost | 1 | 2016 | 19 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2018 | 379 | 0.120 |
Why?
|
| Semantics | 1 | 2016 | 57 | 0.120 |
Why?
|
| Vascular Patency | 1 | 2016 | 139 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 772 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 671 | 0.120 |
Why?
|
| Cardiology | 1 | 2017 | 168 | 0.120 |
Why?
|
| Prognosis | 2 | 2020 | 1748 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 835 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2016 | 298 | 0.110 |
Why?
|
| Cells, Cultured | 2 | 2016 | 2157 | 0.110 |
Why?
|
| Infarction, Posterior Cerebral Artery | 1 | 2013 | 7 | 0.110 |
Why?
|
| Adenosine Diphosphate | 1 | 2013 | 42 | 0.100 |
Why?
|
| Medicare | 1 | 2018 | 612 | 0.100 |
Why?
|
| Temporal Lobe | 1 | 2013 | 45 | 0.100 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2013 | 24 | 0.100 |
Why?
|
| Long QT Syndrome | 1 | 2013 | 32 | 0.100 |
Why?
|
| Acute Disease | 1 | 2015 | 671 | 0.100 |
Why?
|
| Cerebral Infarction | 1 | 2013 | 83 | 0.100 |
Why?
|
| Prevalence | 3 | 2024 | 1380 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 724 | 0.100 |
Why?
|
| Thromboxanes | 2 | 2022 | 9 | 0.100 |
Why?
|
| Stroke | 2 | 2021 | 1196 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 455 | 0.090 |
Why?
|
| Comorbidity | 1 | 2015 | 1120 | 0.090 |
Why?
|
| Jugular Veins | 1 | 2011 | 29 | 0.090 |
Why?
|
| Hospitalization | 3 | 2024 | 1364 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2011 | 60 | 0.090 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2011 | 26 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 115 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2011 | 187 | 0.080 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2010 | 43 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 1 | 2011 | 209 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2025 | 873 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 2175 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2021 | 768 | 0.070 |
Why?
|
| Survival Rate | 2 | 2018 | 851 | 0.060 |
Why?
|
| Incidence | 2 | 2018 | 1377 | 0.050 |
Why?
|
| Pericardium | 1 | 2023 | 35 | 0.050 |
Why?
|
| Heart Atria | 1 | 2023 | 137 | 0.050 |
Why?
|
| Creatinine | 1 | 2022 | 134 | 0.050 |
Why?
|
| Inpatients | 1 | 2024 | 305 | 0.040 |
Why?
|
| Troponin | 1 | 2020 | 38 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2023 | 406 | 0.040 |
Why?
|
| Critical Care | 1 | 2023 | 396 | 0.040 |
Why?
|
| Diastole | 1 | 2019 | 91 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 1276 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 7 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2017 | 33 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 71 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 641 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 195 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 418 | 0.030 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2018 | 318 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 2334 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1654 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 409 | 0.020 |
Why?
|
| Paracrine Communication | 1 | 2011 | 15 | 0.020 |
Why?
|
| Thrombomodulin | 1 | 2011 | 17 | 0.020 |
Why?
|
| Protein C | 1 | 2011 | 26 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2011 | 48 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2011 | 61 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2011 | 110 | 0.020 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2011 | 61 | 0.020 |
Why?
|
| Rabbits | 1 | 2011 | 333 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 2010 | 55 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2010 | 66 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2010 | 129 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2011 | 1537 | 0.010 |
Why?
|
| Animals | 1 | 2011 | 20663 | 0.010 |
Why?
|